ATE507302T1 - Verfahren zur antikörpererzeugung - Google Patents

Verfahren zur antikörpererzeugung

Info

Publication number
ATE507302T1
ATE507302T1 AT05851359T AT05851359T ATE507302T1 AT E507302 T1 ATE507302 T1 AT E507302T1 AT 05851359 T AT05851359 T AT 05851359T AT 05851359 T AT05851359 T AT 05851359T AT E507302 T1 ATE507302 T1 AT E507302T1
Authority
AT
Austria
Prior art keywords
antibody
amino acid
methods
acid sequence
substitutable position
Prior art date
Application number
AT05851359T
Other languages
English (en)
Inventor
Fernando Jose Rebelo Do Couto
Kristin B Hendricks
Stacey Ellen Wallace
Guo-Liang Yu
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Application granted granted Critical
Publication of ATE507302T1 publication Critical patent/ATE507302T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05851359T 2004-11-08 2005-11-02 Verfahren zur antikörpererzeugung ATE507302T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/984,473 US7462697B2 (en) 2004-11-08 2004-11-08 Methods for antibody engineering
PCT/US2005/039930 WO2006050491A2 (en) 2004-11-08 2005-11-02 Methods for antibody engineering

Publications (1)

Publication Number Publication Date
ATE507302T1 true ATE507302T1 (de) 2011-05-15

Family

ID=36316567

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851359T ATE507302T1 (de) 2004-11-08 2005-11-02 Verfahren zur antikörpererzeugung

Country Status (12)

Country Link
US (5) US7462697B2 (de)
EP (1) EP1819830B1 (de)
JP (2) JP2008518619A (de)
CN (2) CN103980362A (de)
AT (1) ATE507302T1 (de)
CA (2) CA2585742C (de)
DE (1) DE602005027737D1 (de)
DK (1) DK1819830T3 (de)
ES (1) ES2362792T3 (de)
HK (1) HK1200854A1 (de)
PT (1) PT1819830E (de)
WO (1) WO2006050491A2 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP3056568B1 (de) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blutpharmakokinetik von antikörpern
AU2007307324B2 (en) * 2006-05-19 2013-08-15 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific B cells
US8280711B2 (en) * 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
TW201531484A (zh) * 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
CN101868477A (zh) * 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
TWI617576B (zh) 2007-05-21 2018-03-11 艾爾德生物控股有限責任公司 介白素-６（ｉｌ-６）的抗體及其等之用途
AU2013204593B2 (en) * 2007-05-21 2016-01-21 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
DK2164961T3 (en) * 2007-06-25 2015-03-02 Esbatech Alcon Biomed Res Unit Sequence based forward position and optimization of single chain ​​antibodies
WO2009000099A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
EA022990B1 (ru) * 2007-08-20 2016-04-29 Глаксо Груп Лимитед Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
CN103992405B (zh) * 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
LT3444274T (lt) * 2008-06-25 2021-03-25 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys tnf
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
CN110372792A (zh) * 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2409990A4 (de) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd Variante einer konstanten antikörperregion
WO2010113117A2 (en) 2009-03-30 2010-10-07 Edimer Biotech S.A. Preparation of isolated agonist anti-edar monoclonal antibodies
EP2424891B1 (de) 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Monoklonale erg-antikörper
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
EP2504030A4 (de) 2009-11-24 2013-06-26 Alderbio Holdings Llc Il-6-antagonisten zur erhöhung von albumin und/oder senkung von crp
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
SMT201900251T1 (it) 2009-12-10 2019-07-11 Regeneron Pharma Topi che producono anticorpi della catena pesante
JP5686817B2 (ja) 2009-12-22 2015-03-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 配列依存性の凝集
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
CN101928345B (zh) * 2010-06-21 2012-08-29 中国科学技术大学 一种人源化抗体及其人源化改造方法
NZ607510A (en) * 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
EP2643016A2 (de) 2010-11-23 2013-10-02 Alder Biopharmaceuticals, Inc. Antikörper gegen il6 zur behandlung von anämie
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
EP2702078B1 (de) 2011-04-29 2018-11-07 Apexigen, Inc. Anti-cd40-antikörper und verfahren zu ihrer verwendung
GB2528401A (en) * 2011-05-06 2016-01-20 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
EP3498732B1 (de) * 2011-05-06 2021-11-17 Zoetis Services LLC Antikörper gegen nervenwachstumsfaktor und verfahren zur herstellung und verwendung davon
JP6208658B2 (ja) 2011-07-05 2017-10-04 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７−抗体結合体および使用方法
US9057728B2 (en) 2011-07-12 2015-06-16 Epitomics, Inc. FACS-based method for obtaining an antibody sequence
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
EP3321281B1 (de) 2011-08-05 2019-11-27 biOasis Technologies Inc P97-fragmente mit transferaktivität
US9988687B2 (en) 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR102027603B1 (ko) 2011-11-02 2019-10-01 아펙시젠, 인코포레이티드 항-kdr 항체 및 사용 방법
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
JP6433424B2 (ja) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
MX2015006616A (es) * 2012-12-05 2016-01-22 Hoffmann La Roche Doble direccion.
CN103145834B (zh) * 2013-01-17 2015-03-18 广州泰诺迪生物科技有限公司 一种抗体人源化改造方法
CN105263958B (zh) 2013-03-13 2019-09-27 比奥阿赛斯技术有限公司 p97片段及其应用
JP6525432B2 (ja) 2013-03-14 2019-06-05 アペクシジェン， インコーポレイテッド 抗ｒａｎｋｌ抗体および使用方法
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10465186B2 (en) 2013-08-19 2019-11-05 Epitomics, Inc. Antibody identification by lineage analysis
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MX383543B (es) * 2013-11-19 2025-03-14 Janssen Biotech Inc Anticuerpo anti-calicreina-2 humanizado.
WO2015084994A1 (en) 2013-12-03 2015-06-11 President And Fellows Of Harvard College Methods and reagents for the assessment of gestational diabetes
AU2015207665B2 (en) 2014-01-17 2021-04-15 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
BR112016017933A2 (pt) 2014-02-03 2017-10-10 Bioasis Technologies Inc ?proteínas de fusão p97?
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
EP3134439B1 (de) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk-antikörpermoleküle und verwendung davon für eine auf syk abzielende therapie
JP6847664B2 (ja) 2014-05-01 2021-03-24 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７−ポリヌクレオチド複合体
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101618458B1 (ko) 2014-11-28 2016-05-10 강원대학교산학협력단 항체에서 항원-항체 결합력과 양의 상관관계를 갖는 아미노산 서열에 대한 정보를 얻는 방법
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
WO2016131058A1 (en) 2015-02-13 2016-08-18 Biommune Technologies Inc. Antibodies to l-type voltage gated channels and related methods
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3394098A4 (de) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin-antikörper und verfahren zur verwendung
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
SG11201807765PA (en) 2016-04-28 2018-10-30 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
AU2017285995B2 (en) * 2016-06-14 2023-11-30 Agency For Science, Technology And Research PRL3 antibody
US20190352426A1 (en) 2016-08-03 2019-11-21 Achaogen, Inc. Plazomicin antibodies and methods of use
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018129451A2 (en) 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
EP3612215B1 (de) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Zusammensetzungen zur behandlung von lungenentzündungen
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CR20240273A (es) 2017-11-01 2024-08-27 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229)
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
EP4603508A3 (de) 2017-12-19 2025-10-29 Surrozen Operating, Inc. Anti-frizzled-antikörper und verfahren zur verwendung
US11078283B2 (en) 2018-01-17 2021-08-03 Apexigen, Inc. Anti-PD-L1 antibodies and methods of use
CN112292394A (zh) 2018-06-08 2021-01-29 文塔纳医疗系统公司 用于改善的功能性和可制造性的通用或归一化抗体框架
WO2020010308A1 (en) 2018-07-05 2020-01-09 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
US11976131B2 (en) * 2018-07-31 2024-05-07 Heidelberg Pharma Research Gmbh Humanized antibodies against PSMA
US12195543B2 (en) 2018-09-11 2025-01-14 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Anti-FLT3 antigen binding proteins
EP3954393A1 (de) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
CN115819575B (zh) * 2022-08-24 2023-06-27 武汉爱博泰克生物科技有限公司 针对人肿瘤坏死因子-α的单克隆抗体
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
EP4646441A1 (de) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-11r-alpha-antikörper zur behandlung von schilddrüsenaugenkrankheit
WO2025179282A1 (en) 2024-02-23 2025-08-28 Flatiron Bio, Llc Antibodies targeting epstein-barr virus proteins and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6093853A (en) * 1997-07-04 2000-07-25 Nok Corporation Phenylenediamine derivative, production method thereof and antioxidant for rubber using it as effective constituent
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US7115716B2 (en) * 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2003093317A1 (en) * 2002-04-30 2003-11-13 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
JP2005535341A (ja) * 2002-08-15 2005-11-24 エピトミスク インコーポレーティッド ヒト化ウサギ抗体
ATE487796T1 (de) * 2003-01-17 2010-11-15 Danisco Verfahren zur in-situ-herstellung eines emulgators in einem nahrungsmittel
DK1594542T3 (da) * 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
EP1599606A1 (de) * 2003-03-03 2005-11-30 Arizona Board of Regents on behalf of The University of Arizona Benutzung von protein thyrosine phosphatase (prl-1) als marker und therapeutisches zielmolekul für pankreaskrebs
AU2003259718A1 (en) * 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering

Also Published As

Publication number Publication date
CA2585742A1 (en) 2006-05-11
DE602005027737D1 (de) 2011-06-09
CA2585742C (en) 2016-04-12
HK1200854A1 (en) 2015-08-14
JP5096611B2 (ja) 2012-12-12
EP1819830A2 (de) 2007-08-22
ES2362792T3 (es) 2011-07-13
US7462697B2 (en) 2008-12-09
CN103980362A (zh) 2014-08-13
US8404816B2 (en) 2013-03-26
CA2901238A1 (en) 2006-05-11
US20120003671A1 (en) 2012-01-05
DK1819830T3 (da) 2011-07-04
CN101080496A (zh) 2007-11-28
WO2006050491A2 (en) 2006-05-11
PT1819830E (pt) 2011-07-20
CA2901238C (en) 2020-03-24
EP1819830B1 (de) 2011-04-27
JP2012095654A (ja) 2012-05-24
US20150038370A1 (en) 2015-02-05
WO2006050491A3 (en) 2006-12-28
EP1819830A4 (de) 2009-03-11
US20090155824A1 (en) 2009-06-18
US10613094B2 (en) 2020-04-07
US20060099204A1 (en) 2006-05-11
US7960517B2 (en) 2011-06-14
US20120329069A1 (en) 2012-12-27
JP2008518619A (ja) 2008-06-05

Similar Documents

Publication Publication Date Title
ATE507302T1 (de) Verfahren zur antikörpererzeugung
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
NL300919I2 (nl) Brodalumab
DK1716178T3 (da) Mindre immunogene bindingsmolekyler
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2008036688A3 (en) Optimized antibodies that target hm1.24
EP2275443A4 (de) Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2008031133A3 (en) Borrelia antigens
EP3202786A3 (de) Sequenzbasierte herstellung und optimierung von einzelkettenantikörpern
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
BRPI0511910A (pt) anticorpos antil-il-13 e complexos
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
WO2013087857A3 (de) Antikörper gegen toxine von c. difficile
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
WO2005000896A3 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof
ATE531799T1 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper
TH1901007069A (th) สารภูมิต้านทาน garp-tgf-บีตา

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties